NO20052010L - Immunogen sammensetning - Google Patents

Immunogen sammensetning

Info

Publication number
NO20052010L
NO20052010L NO20052010A NO20052010A NO20052010L NO 20052010 L NO20052010 L NO 20052010L NO 20052010 A NO20052010 A NO 20052010A NO 20052010 A NO20052010 A NO 20052010A NO 20052010 L NO20052010 L NO 20052010L
Authority
NO
Norway
Prior art keywords
immunogenic composition
ipv
antigenicity
immunogenicity
retains
Prior art date
Application number
NO20052010A
Other languages
English (en)
Other versions
NO20052010D0 (no
Inventor
Jean Stephenne
Yves Mayeresse
Original Assignee
Glaxosmithkline Biolog Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32234471&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052010(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0225543A external-priority patent/GB0225543D0/en
Priority claimed from GBGB0225520.6A external-priority patent/GB0225520D0/en
Priority claimed from GB0225532A external-priority patent/GB0225532D0/en
Priority claimed from GB0317381A external-priority patent/GB0317381D0/en
Priority claimed from GB0317371A external-priority patent/GB0317371D0/en
Priority claimed from GB0317380A external-priority patent/GB0317380D0/en
Application filed by Glaxosmithkline Biolog Sa filed Critical Glaxosmithkline Biolog Sa
Publication of NO20052010D0 publication Critical patent/NO20052010D0/no
Publication of NO20052010L publication Critical patent/NO20052010L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/04—Preserving or maintaining viable microorganisms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/125—Picornaviridae, e.g. calicivirus
    • A61K39/13—Poliovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Disinfection or sterilisation of materials or objects, in general; Accessories therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Sampling And Sample Adjustment (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

SAMMENDRAG Foreliggende oppfinnelse angår immunogene sammensetninger omfattende et "tørket fast stoff" eller svært viskøs væske" formulering av inaktivert poliovirus (IPV) og et stabiliserende middel hvori IPV bibeholder sin antigenisitet og/eller i.mmunogenisitet. Fremgangsmåter for fremstilling av en tørket formulering av IPV som bibeholder sin antigenisitet/immunogenisitet er beskrevet.
NO20052010A 2002-11-01 2005-04-25 Immunogen sammensetning NO20052010L (no)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GB0225543A GB0225543D0 (en) 2002-11-01 2002-11-01 Immunogenic composition
GBGB0225520.6A GB0225520D0 (en) 2002-11-01 2002-11-01 Drying process
GB0225532A GB0225532D0 (en) 2002-11-01 2002-11-01 Drying process
GB0317381A GB0317381D0 (en) 2003-07-24 2003-07-24 Drying method
GB0317371A GB0317371D0 (en) 2003-07-24 2003-07-24 Immunogenic composition
GB0317380A GB0317380D0 (en) 2003-07-24 2003-07-24 Drying method
PCT/EP2003/012160 WO2004039399A1 (en) 2002-11-01 2003-10-30 Immunogenic composition

Publications (2)

Publication Number Publication Date
NO20052010D0 NO20052010D0 (no) 2005-04-25
NO20052010L true NO20052010L (no) 2005-06-24

Family

ID=32234471

Family Applications (3)

Application Number Title Priority Date Filing Date
NO20052010A NO20052010L (no) 2002-11-01 2005-04-25 Immunogen sammensetning
NO20051998A NO342741B1 (no) 2002-11-01 2005-04-25 Fremgangsmåte for konservering av et aktivt agens, svært viskøs væske, immunogen sammensetning eller vaksine, fremgangsmåte for fremstilling av en vaksine samt kit.
NO20180874A NO344759B1 (no) 2002-11-01 2018-06-21 Fremgangsmåte for konservering av et aktivt agens.

Family Applications After (2)

Application Number Title Priority Date Filing Date
NO20051998A NO342741B1 (no) 2002-11-01 2005-04-25 Fremgangsmåte for konservering av et aktivt agens, svært viskøs væske, immunogen sammensetning eller vaksine, fremgangsmåte for fremstilling av en vaksine samt kit.
NO20180874A NO344759B1 (no) 2002-11-01 2018-06-21 Fremgangsmåte for konservering av et aktivt agens.

Country Status (27)

Country Link
US (3) US8409587B2 (no)
EP (3) EP1556477B1 (no)
JP (2) JP2006504801A (no)
KR (2) KR101058978B1 (no)
AR (2) AR041881A1 (no)
AT (1) ATE352316T1 (no)
AU (2) AU2003278166B2 (no)
BR (1) BR0315767A (no)
CA (2) CA2503871C (no)
CY (2) CY1119504T1 (no)
DE (1) DE60311526T2 (no)
DK (2) DK1556477T3 (no)
ES (3) ES2645924T3 (no)
HU (1) HUE034801T2 (no)
IL (2) IL168052A (no)
IS (2) IS7806A (no)
LT (2) LT2395073T (no)
MA (2) MA27551A1 (no)
MX (3) MXPA05004528A (no)
MY (2) MY132859A (no)
NO (3) NO20052010L (no)
NZ (2) NZ539706A (no)
PL (2) PL213647B1 (no)
PT (2) PT1556477T (no)
SI (2) SI1556477T1 (no)
TW (2) TWI332843B (no)
WO (2) WO2004039399A1 (no)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1556477T3 (en) * 2002-11-01 2017-10-23 Glaxosmithkline Biologicals Sa Process for drying
US20060099567A1 (en) * 2004-04-08 2006-05-11 Biomatrica, Inc. Integration of sample storage and sample management for life science
WO2005113147A2 (en) * 2004-04-08 2005-12-01 Biomatrica, Inc. Integration of sample storage and sample management for life science
US20080176209A1 (en) * 2004-04-08 2008-07-24 Biomatrica, Inc. Integration of sample storage and sample management for life science
GB0409795D0 (en) * 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
TWI398272B (zh) * 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
GB0505518D0 (en) * 2005-03-17 2005-04-27 Chiron Srl Combination vaccines with whole cell pertussis antigen
US9486515B2 (en) 2005-06-27 2016-11-08 Glaxosmithkline Biologicals S.A. Immunogenic composition
US8968721B2 (en) 2005-12-28 2015-03-03 Advanced Bionutrition Corporation Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same
EP1973406B1 (en) 2005-12-28 2014-03-12 Advanced Bionutrition Corporation A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form
EP2491947A3 (en) * 2006-09-07 2012-10-17 GlaxoSmithKline Biologicals S.A. Vaccine
CA2673120C (en) 2006-12-18 2012-08-07 Advanced Bionutrition Corporation A dry food product containing live probiotic
WO2008135514A1 (en) 2007-05-02 2008-11-13 Glaxosmithkline Biologicals S.A. Vaccine
EP2148923B1 (en) * 2007-05-18 2012-08-22 MedImmune, LLC Preservation of bioactive materials by freeze dried foam
WO2008155529A1 (en) * 2007-06-16 2008-12-24 Enigma Diagnostics Limited Compositions
GB0711683D0 (en) * 2007-06-16 2007-07-25 Enigma Diagnostics Ltd Compositions
KR101540920B1 (ko) 2007-07-26 2015-08-03 사노피 파스퇴르 리미티드 항원-애주번트 조성물 및 방법
GB0822633D0 (en) * 2008-12-11 2009-01-21 Novartis Ag Formulation
US9623094B2 (en) 2009-03-27 2017-04-18 Advanced Bionutrition Corporation Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish
KR101799983B1 (ko) 2009-05-26 2017-12-20 어드밴스드 바이오뉴트리션 코프. 생물학적 활성 미생물 및/또는 생활성 물질을 포함하는 안정한 건식분말 조성물 및 제조 방법
EP2475393A4 (en) * 2009-09-14 2013-08-21 Vu Truong-Le FORMULATION FOR THE ROOM TEMPERATURE STABILIZATION OF A WEAKED LIVING BACTERIAL VACCINE
US9504750B2 (en) 2010-01-28 2016-11-29 Advanced Bionutrition Corporation Stabilizing composition for biological materials
WO2011094469A2 (en) 2010-01-28 2011-08-04 Advanced Bionutrition Corporation Dry glassy composition comprising a bioactive material
FR2960781B1 (fr) 2010-06-07 2013-11-22 Sanofi Pasteur Preparation d'un vaccin oral sec stabilise, compose d'un virus vivant attenue
EP2598661B1 (en) 2010-07-26 2017-09-27 Biomatrica, INC. Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures
WO2012018638A2 (en) 2010-07-26 2012-02-09 Biomatrica, Inc. Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures
CL2011001984A1 (es) 2010-08-13 2012-06-29 Advanced Bionutrition Corp Composicion seca estabilizadora para material biologico que comprende carbohidrato, proteinas hidrolizadas de animal o de planta y un componente de acido carboxilico; metodo de preparacion; y formulacion de entrega oral que comprende la composicion seca estabilizadora.
WO2012028315A1 (en) 2010-09-02 2012-03-08 Sanofi Pasteur Sa A stabilizer for the preparation of a dry polio injectable vaccine composition
CA2819246C (en) 2010-12-02 2023-04-25 Oncolytics Biotech Inc. Liquid viral formulations
US9044498B2 (en) 2010-12-02 2015-06-02 Oncolytics Biotech Inc. Lyophilized viral formulations
US20120222979A1 (en) 2011-03-04 2012-09-06 Elwha LLC, a limited liability company of the State of Delaware Glassy compositions
EP2694100A4 (en) * 2011-04-07 2014-10-01 Glaxosmithkline Llc FORMULATIONS HAVING REDUCED VISCOSITY
BR112013025845A2 (pt) * 2011-04-07 2018-09-04 Glaxosmithkline Llc formulações com viscosidade reduzida
CN102793919A (zh) 2011-05-20 2012-11-28 日东电工株式会社 医药组合物及医药组合物的制造方法
PE20191242A1 (es) 2011-10-25 2019-09-16 Prothena Biosciences Ltd Formulaciones de anticuerpo y metodos
EP2934572A4 (en) 2012-12-20 2016-11-23 Biomatrica Inc FORMULATIONS AND METHODS FOR STABILIZING PCR REAGENTS
EP3053594A4 (en) * 2013-10-03 2017-05-10 Nitto Denko Corporation Dried influenza vaccine preparation and method for producing dried influenza vaccine preparation
CN105899220B (zh) * 2013-12-19 2020-01-10 扬森疫苗与预防公司 改进的病毒体配制品
CA2938495A1 (en) 2014-02-11 2015-08-20 Massachusetts Institute Of Technology Full spectrum anti-dengue antibody
JP6661554B2 (ja) 2014-06-10 2020-03-11 バイオマトリカ，インク． 周囲温度における血小板の安定化
AR101256A1 (es) * 2014-07-21 2016-12-07 Sanofi Pasteur Composición vacunal que comprende ipv y ciclodextrinas
MX380541B (es) 2015-06-30 2025-03-12 Soc Des Produits Nestle S A Star Composición adecuada para proteger microorganismos.
US12558395B2 (en) 2015-07-29 2026-02-24 Advanced Bionutrition Corp. Stable dry probiotic compositions for special dietary uses
BR112018001784B1 (pt) 2015-07-29 2022-05-10 Advanced Bionutrition Corp Composições probióticas secas estáveis para usos dietéticos especiais, seu método de preparação e método de preparação de uma fórmula para bebês
BR112018004400A2 (pt) 2015-09-04 2018-12-04 Inventprise Llc composições de vacina vlp estabilizadas
JP6827048B2 (ja) 2015-12-08 2021-02-10 バイオマトリカ，インク． 赤血球沈降速度の低下
AU2017321863B2 (en) 2016-09-02 2024-07-11 Sanofi Vaccines US Inc. Neisseria meningitidis vaccine
EP3781192A1 (en) * 2018-04-16 2021-02-24 Merck Patent GmbH Additives for protein formulations to improve thermal stability
AU2019345595A1 (en) * 2018-09-28 2021-04-15 Otsuka Pharmaceutical Factory,Inc. Mammal cell preserving solution containing acarbose or stachyose
CN113194989B (zh) 2018-12-20 2024-01-30 英特维特国际股份有限公司 初免-强化免疫接种方案

Family Cites Families (88)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US509893A (en) * 1893-12-05 William griesser
DE1157734B (de) 1961-08-16 1963-11-21 Behringwerke Ag Verfahren zur Herstellung von haltbaren, oral zu verabreichenden Poliomyelitisvirus-Praeparaten
US3767790A (en) 1972-02-11 1973-10-23 Nat Patent Dev Corp Microorganisms
US3929132A (en) * 1973-04-10 1975-12-30 Alza Corp Osmotic dispenser
EP0027888B1 (en) 1979-09-21 1986-04-16 Hitachi, Ltd. Semiconductor switch
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
GB8323094D0 (en) * 1983-08-26 1983-09-28 Franks F Preservation of cells
WO1987000196A1 (en) 1985-07-09 1987-01-15 Quadrant Bioresources Limited Protection of proteins and the like
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
GB8604983D0 (en) * 1986-02-28 1986-04-09 Biocompatibles Ltd Protein preservation
GB8715238D0 (en) 1987-06-29 1987-08-05 Quadrant Bioresources Ltd Food process
GB8801338D0 (en) 1988-01-21 1988-02-17 Quadrant Bioresources Ltd Preservation of viruses
DE3819530A1 (de) * 1988-06-08 1989-12-21 Westphal Geb Jauch Christel Dr Verfahren, traeger und testsatz fuer die kultivierung und mikroskopische untersuchung von zellen
DE68929323T2 (de) 1988-12-16 2002-04-18 De Staat Der Nederlanden Vertegenwoordigd Door De Minister Van Welzijn, Volksgezondheid En Cultuur Pneumolysin-mutanten und pneumokokken-impfstoffe daraus
ZA907737B (en) 1989-09-29 1991-07-31 Nisshin Oil Mills Ltd Stable immunogen composition for oral administration
JPH03161441A (ja) 1989-11-20 1991-07-11 Senjiyu Seiyaku Kk メイラード反応阻害剤
CA2087160A1 (en) 1990-07-16 1992-01-17 P. Frederick Sparling Antigenic iron repressible proteins from n. meningitidis related to the hemolysin family of toxins
US5912336A (en) 1990-08-23 1999-06-15 University Of North Carolina At Chapel Hill Isolated nucleic acid molecules encoding transferrin binding proteins from Neisseria gonorrhoeae and Neisseria meningitidis
ATE253114T1 (de) 1990-08-23 2003-11-15 Univ North Carolina Transferrin bindende proteine aus neisseria- gonorrhoeae und neisseria-meningitidis
US5153312A (en) 1990-09-28 1992-10-06 American Cyanamid Company Oligosaccharide conjugate vaccines
US5476929A (en) 1991-02-15 1995-12-19 Uab Research Foundation Structural gene of pneumococcal protein
US6592876B1 (en) 1993-04-20 2003-07-15 Uab Research Foundation Pneumococcal genes, portions thereof, expression products therefrom, and uses of such genes, portions and products
FR2682041B1 (fr) 1991-10-03 1994-01-14 Pasteur Merieux Serums Vaccins Vaccin contre les infections a neisseria meningitidis.
IT1253009B (it) 1991-12-31 1995-07-10 Sclavo Ricerca S R L Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini
WO1993015760A1 (en) 1992-02-11 1993-08-19 U.S. Government, As Represented By The Secretary Of The Army Dual carrier immunogenic construct
AU3630093A (en) 1992-03-02 1993-10-05 Biocine S.P.A. Helicobacter pylori proteins useful for vaccines and diagnostics
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
JP3626996B2 (ja) 1992-05-23 2005-03-09 グラクソスミスクライン・バイオロジカルス・ソシエテ・アノニム Ｂ型肝炎表面抗原および他の抗原からなる複合ワクチン
FR2692592B1 (fr) 1992-06-19 1995-03-31 Pasteur Merieux Serums Vacc Fragments d'ADN codant pour les sous-unités du récepteur de la transferrine de Neisseria meningitidis et procédés les exprimant.
SG47725A1 (en) 1992-10-27 1998-04-17 American Cyanamid Co Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
DK0699076T3 (da) 1993-05-18 2003-03-03 Univ Ohio State Res Found Vaccine mod mellemørebetændelse
AU3191495A (en) 1994-08-09 1996-03-07 Nisshin Oil Mills, Ltd., The Peroral immunogen composition and process for producing the same
US5565204A (en) 1994-08-24 1996-10-15 American Cyanamid Company Pneumococcal polysaccharide-recombinant pneumolysin conjugate vaccines for immunization against pneumococcal infections
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6265567B1 (en) 1995-04-07 2001-07-24 University Of North Carolina At Chapel Hill Isolated FrpB nucleic acid molecule
US5843464A (en) 1995-06-02 1998-12-01 The Ohio State University Synthetic chimeric fimbrin peptides
JPH11507214A (ja) 1995-06-07 1999-06-29 バイオケム ヴァシーンズ インク． Ｈｓｐ７０ファミリーに属する連鎖球菌の熱ショック蛋白質メンバー
DE69615362T3 (de) 1995-06-07 2006-07-20 Smithkline Beecham Biologicals S.A. Impfstoff mit einem polysaccharidantigen-trägerprotein-konjugat und einem trägerprotein
ATE239451T1 (de) * 1995-06-07 2003-05-15 Elan Drug Delivery Ltd Verfahren zur stabilen einarbeitung von substanzen in trockene geschäumte glasmatrizen und auf diese weise hergestellte zusammensetzungen
IL122588A (en) * 1995-06-23 2001-12-23 Smithkline Beecham Biolog A combination vaccine containing a polysaccharide conjugated antigen attached to a phosphate aluminum and one or more additional antibodies
DE19543770C2 (de) 1995-11-24 1998-11-05 Metallgesellschaft Ag Vorrichtung zur Messung von kondensierter Feuchtigkeit in Vorrichtungen und/oder Rohrleitungen der chemischen Technik und deren Verwendung
AU1671197A (en) * 1996-02-13 1997-09-02 Nisshin Oil Mills, Ltd., The Vaccine-containing emulsion and vaccine-containing powder for oral administration and process for producing the same
EP0912608B1 (en) 1996-05-01 2006-04-19 The Rockefeller University Choline binding proteins for anti-pneumococcal vaccines
US5766520A (en) * 1996-07-15 1998-06-16 Universal Preservation Technologies, Inc. Preservation by foam formation
AU3214597A (en) * 1996-05-29 1998-01-05 Universal Preservation Technologies, Inc. Long-term shelf preservation by vitrification
BR9710460A (pt) 1996-07-02 1999-08-17 Connaught Lab Composi-Æo imunolÄgica multi-valente e seu uso em vacinas
FR2751000B1 (fr) 1996-07-12 1998-10-30 Inst Nat Sante Rech Med Adn specifiques des bacteries de l'espece neisseria meningitidis, leurs procedes d'obtention et leurs applications biologiques
DE19630390A1 (de) 1996-07-26 1998-01-29 Chiron Behring Gmbh & Co Proteine, insbesondere Membranproteine von Helicobacter pylori, ihre Herstellung und Verwendung
US5882871A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation Saliva binding protein
US5882896A (en) 1996-09-24 1999-03-16 Smithkline Beecham Corporation M protein
PT942983E (pt) 1996-10-31 2007-02-28 Human Genome Sciences Inc Antigénios e vacinas de streptococcus pneumoniae
US6051238A (en) * 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
US6299881B1 (en) 1997-03-24 2001-10-09 Henry M. Jackson Foundation For The Advancement Of Military Medicine Uronium salts for activating hydroxyls, carboxyls, and polysaccharides, and conjugate vaccines, immunogens, and other useful immunological reagents produced using uronium salts
SE511963C2 (sv) 1997-04-23 1999-12-20 Ericsson Telefon Ab L M Anordning och förfarande för bestämning av linjespänning i en abonnentlinjekrets
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
EP0998557A2 (en) 1997-07-21 2000-05-10 North American Vaccine, Inc. Modified immunogenic pneumolysin, compositions and their use as vaccines
GB9717953D0 (en) 1997-08-22 1997-10-29 Smithkline Beecham Biolog Vaccine
AU4707097A (en) * 1997-09-15 1999-04-05 Pasteur Merieux Serums Et Vaccins Multivalent vaccines
ES2278420T3 (es) 1997-11-21 2007-08-01 Serono Genetics Institute S.A. Secuencia genomica y polipeptidos de chlamydia pneumoniae, fragmentos de los mismos y uso de los mismos, en particular para diagnostico, prevencion y tratamiento de infeccion.
AU5459698A (en) * 1997-11-26 1999-06-15 Universal Preservation Technologies, Inc. Preservation of sensitive biological samples by vitrification
CN1280619A (zh) 1997-11-28 2001-01-17 根瑟特公司 沙眼衣原体的基因组序列和多肽,其片段以及其用途,特别是用于诊断、预防和治疗感染
GB9726398D0 (en) 1997-12-12 1998-02-11 Isis Innovation Polypeptide and coding sequences
AU1979599A (en) 1998-01-14 1999-08-02 Chiron S.P.A. (neisseria meningitidis) antigens
GB9806456D0 (en) 1998-03-25 1998-05-27 Smithkline Beecham Biolog Vaccine composition
US6503511B1 (en) 1998-04-07 2003-01-07 Medimmune, Inc. Derivatives of choline binding proteins for vaccines
GB9807721D0 (en) 1998-04-08 1998-06-10 Chiron Spa Antigen
CN100379757C (zh) 1998-05-01 2008-04-09 希龙公司 脑膜炎奈瑟球菌抗原和组合物
US6306345B1 (en) * 1998-05-06 2001-10-23 Universal Preservation Technologies, Inc. Industrial scale barrier technology for preservation of sensitive biological materials at ambient temperatures
JP2004511201A (ja) 1998-10-09 2004-04-15 カイロン　コーポレイション ナイセリアゲノム配列およびそれらの使用方法
EP1123403A1 (en) 1998-10-22 2001-08-16 The University Of Montana OMP85 PROTEINS OF $i(NEISSERIA GONORRHOEAE) AND $i(NEISSERIA MENINGITIDIS), COMPOSITIONS CONTAINING SAME AND METHODS OF USE THEREOF
AU1722300A (en) 1998-11-12 2000-05-29 Regents Of The University Of California, The Chlamydia pneumoniae genome sequence
GB9828000D0 (en) 1998-12-18 1999-02-10 Chiron Spa Antigens
KR100642044B1 (ko) 1999-03-19 2006-11-10 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
US6245568B1 (en) 1999-03-26 2001-06-12 Merck & Co., Inc. Human papilloma virus vaccine with disassembled and reassembled virus-like particles
EP1165796A2 (en) 1999-04-09 2002-01-02 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
ES2307553T3 (es) 1999-12-02 2008-12-01 Novartis Vaccines And Diagnostics, Inc. Composiciones y procedimientos para estabilizar moleculas biologicas tras liofilizacion.
CA2871789C (en) 2000-01-17 2017-04-04 Novartis Vaccines And Diagnostics S.R.L. Outer membrane vesicle (omv) vaccine comprising n. meningitidis serogroup b outer membrane proteins
ES2281409T3 (es) 2000-02-28 2007-10-01 Novartis Vaccines And Diagnostics S.R.L. Expresion heterologa de proteinas de neisseria.
OA12302A (en) * 2000-06-29 2003-10-24 Glaxosmithkline Biolog Sa Multivalent vaccine composition.
ATE440861T1 (de) 2000-07-03 2009-09-15 Novartis Vaccines & Diagnostic Immunisierung gegen chlamydia pneumoniae
KR100385711B1 (ko) 2000-07-05 2003-05-27 녹십자백신 주식회사 디프테리아, 파상풍 톡소이드와 백일해균 및ｂ형간염표면항원을 포함한 4가 혼합백신 및 그 제조방법
US7939087B2 (en) 2000-10-27 2011-05-10 Novartis Vaccines And Diagnostics, Inc. Nucleic acids and proteins from Streptococcus groups A & B
WO2003009869A1 (en) 2001-07-26 2003-02-06 Chiron Srl. Vaccines comprising aluminium adjuvants and histidine
EP1494651A4 (en) * 2002-04-11 2010-10-13 Medimmune Vaccines Inc PRESERVATION OF BIOACTIVE MATERIALS WITH FREEZZED FOAM
DK1556477T3 (en) * 2002-11-01 2017-10-23 Glaxosmithkline Biologicals Sa Process for drying
GB0409795D0 (en) 2004-04-30 2004-06-09 Glaxosmithkline Biolog Sa Drying method
US9473463B2 (en) 2014-07-29 2016-10-18 Combined Conditional Access Development & Support, LLC Control word and associated entitlement control message caching and reuse

Also Published As

Publication number Publication date
NO20180874A1 (no) 2005-06-24
KR20050084626A (ko) 2005-08-26
ES2649048T3 (es) 2018-01-09
US20060127415A1 (en) 2006-06-15
MA27551A1 (fr) 2005-10-03
IS7806A (is) 2005-04-18
WO2004039417A3 (en) 2004-12-16
PL215237B1 (pl) 2013-11-29
EP2395073A3 (en) 2012-01-25
WO2004039417A2 (en) 2004-05-13
MY145693A (en) 2012-03-30
KR101058978B1 (ko) 2011-08-23
HK1085380A1 (en) 2006-08-25
US8409587B2 (en) 2013-04-02
NO344759B1 (no) 2020-04-14
SI2395073T1 (sl) 2017-12-29
EP2395073B1 (en) 2017-09-06
JP2006504801A (ja) 2006-02-09
AU2003287980A1 (en) 2004-05-25
DK2395073T3 (en) 2017-10-23
WO2004039399A1 (en) 2004-05-13
HUE034801T2 (en) 2018-02-28
IL168052A (en) 2015-03-31
JP2006512406A (ja) 2006-04-13
CA2503946C (en) 2016-08-16
NO20051998L (no) 2005-06-24
PL213647B1 (pl) 2013-04-30
ES2645924T3 (es) 2017-12-11
MXPA05004528A (es) 2005-07-26
AR041881A1 (es) 2005-06-01
NO342741B1 (no) 2018-08-06
SI1556477T1 (sl) 2017-12-29
EP1556477A2 (en) 2005-07-27
MX343419B (es) 2016-11-04
KR20050075766A (ko) 2005-07-21
PT1556477T (pt) 2017-11-14
KR101130948B1 (ko) 2012-03-30
EP1556477B1 (en) 2017-08-09
IL168052A0 (en) 2011-08-01
CY1119362T1 (el) 2018-03-07
NZ539706A (en) 2008-03-28
CY1119504T1 (el) 2018-03-07
TW200501980A (en) 2005-01-16
MXPA05004675A (es) 2005-06-08
IS7805A (is) 2005-04-18
MA27644A1 (fr) 2005-12-01
IS3028B (is) 2021-05-15
US8449865B2 (en) 2013-05-28
US7927858B2 (en) 2011-04-19
AR041880A1 (es) 2005-06-01
BR0315767A (pt) 2005-09-06
MY132859A (en) 2007-10-31
US20060127414A1 (en) 2006-06-15
ES2280809T3 (es) 2007-09-16
CA2503871A1 (en) 2004-05-13
TW200501981A (en) 2005-01-16
LT1556477T (lt) 2017-10-25
TWI332843B (en) 2010-11-11
CA2503871C (en) 2012-12-11
EP1575612B1 (en) 2007-01-24
PL376950A1 (pl) 2006-01-09
NO20051998D0 (no) 2005-04-25
AU2003287980B2 (en) 2009-06-25
JP4579156B2 (ja) 2010-11-10
ATE352316T1 (de) 2007-02-15
DK1556477T3 (en) 2017-10-23
PL377170A1 (pl) 2006-01-23
AU2003278166A1 (en) 2004-05-25
DE60311526T2 (de) 2007-10-31
AU2003278166B2 (en) 2009-01-29
PT2395073T (pt) 2017-11-24
NZ539613A (en) 2008-09-26
NO20052010D0 (no) 2005-04-25
CA2503946A1 (en) 2004-05-13
US20110159038A1 (en) 2011-06-30
EP2395073A2 (en) 2011-12-14
IL168054A (en) 2011-06-30
LT2395073T (lt) 2017-11-10
DE60311526D1 (de) 2007-03-15
EP1575612A1 (en) 2005-09-21

Similar Documents

Publication Publication Date Title
NO20052010L (no) Immunogen sammensetning
NO20005051L (no) Adjuvantsammensetninger
BR0108058A (pt) Corpo maciço
ATE290059T1 (de) Tensidzusammensetzung enthaltend geminitenside und co-amphiphile, ihre herstellung und ihre verwendung
BR0311599A (pt) composição cimentìcia, éter de celulose e método para controlar o tempo de cura de uma composição cimentìcia contendo éter de celulose
NO20076638L (no) Nye 8-sulfonylamino-3-aminosubstituerte kroman- eller tetrahydronaftalenderivater som modulerer 5HT6-reseptoren
BR9707064A (pt) Novos derivados 19-nor-pregneno
BR0316860A (pt) Composição curável, e composição curável por calor
BR9814229A (pt) Composição cosmética
MX9204522A (es) Derivados 4-benzoil-isoxazol, procedimiento para su preparacion y composicion herbicida que los contiene.
NO942134L (no) Dentalprotese
FI941964L (fi) Pitkäketjuiset alfa-asetyleenialkoholit hydrosilylointireaktion estoaineina ja niiden käyttäminen stabiilien, kovettuvien silikonikoostumusten valmistukseen
BR0011931A (pt) Composição de cura oxidativa ambiente, e, processo para preparar uma a mesma
BR0211390A (pt) Tratamento de infecções da unha com no
BR0106661A (pt) Utilização de copolìmeros etilênicos sequenciados com caráter elástico e composição cosmética
ES2105551T3 (es) Utilizacion de derivados de la resorcina substituidos en posicion(es) 4,4 y 5 o 4 y 6 en unas composiciones cosmeticas o dermofarmaceuticas con accion despigmentante.
NO996479L (no) Kjemiske formuleringer for inkorporering i adhesiver anvendt ved fremstillingen av trematerialer eller tresammensetninger
BR0016952A (pt) Compostos derivados de fenil-piperazina substituìdos, composição farmacêutica, uso e método
DK1446112T3 (da) Anvendelse af glutamat, glutamatderivater eller metabolitter, glutamatanaloger eller blandinger deraf til fremstilling af en sammensætning til behandling af osteoporose
PT792165E (pt) Composicoes imunogenicas
DK0977716T3 (da) Anvendelse af alkoholer som additiver til puds og/eller mørtel
BR0215048A (pt) Composições farmacêuticas à base de derivados de azetidina
DE60028571D1 (de) Dentalporzellan
AR018867A1 (es) Composicion farmaceutica, uso de la composicion, estuche, uso de los compuestos para preparar la composicion y el estuche
AU591932B2 (en) Nematicidal compositions

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application